Veracyte, Inc. (VCYT) stock
VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3034% below fair value
$24.23+0.22 (+0.92%)
Close on Nov 17, 2026Market cap $1.95BP/E 17.3Yield –
Veracyte ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Veracyte's ebitda for the twelve months ending Jun 30, 2026 was $126.60M, up 243.9% year over year. For fiscal 2025 it was $79.19M, up 100.0% from the year before. The highest annual figure on record is $79.19M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $79.19M | +100.0% |
| FY2024 | Dec 31, 2024 | $39.60M | – |
| FY2023 | Dec 31, 2023 | -$58.61M | – |
| FY2022 | Dec 31, 2022 | -$15.15M | – |
| FY2021 | Dec 31, 2021 | -$62.31M | – |
| FY2020 | Dec 31, 2020 | -$27.45M | – |
| FY2019 | Dec 31, 2019 | -$11.01M | – |
| FY2018 | Dec 31, 2018 | -$18.31M | – |
| FY2017 | Dec 31, 2017 | -$22.70M | – |
| FY2016 | Dec 31, 2016 | -$25.29M | – |
| FY2015 | Dec 31, 2015 | -$31.21M | – |
| FY2014 | Dec 31, 2014 | -$27.83M | – |
| FY2013 | Dec 31, 2013 | -$22.17M | – |
| FY2012 | Dec 31, 2012 | -$18.22M | – |
| FY2011 | Dec 31, 2011 | -$14.66M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $27.82M | +12487.3% |
| Q1 FY2026 | Mar 31, 2026 | $28.08M | +239.7% |
| Q4 FY2025 | Dec 31, 2025 | $42.49M | +307.5% |
| Q3 FY2025 | Sep 30, 2025 | $28.21M | +57.7% |
| Q2 FY2025 | Jun 30, 2025 | $221.00K | -97.9% |
| Q1 FY2025 | Mar 31, 2025 | $8.27M | +785.0% |
| Q4 FY2024 | Dec 31, 2024 | $10.43M | – |
| Q3 FY2024 | Sep 30, 2024 | $17.90M | – |
| Q2 FY2024 | Jun 30, 2024 | $10.34M | – |
| Q1 FY2024 | Mar 31, 2024 | $934.00K | – |
| Q4 FY2023 | Dec 31, 2023 | -$29.17M | -2667.9% |
| Q3 FY2023 | Sep 30, 2023 | -$24.42M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.19M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.83M | – |
| Q4 FY2022 | Dec 31, 2022 | $1.14M | – |
| Q3 FY2022 | Sep 30, 2022 | -$3.36M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.24M | – |
| Q1 FY2022 | Mar 31, 2022 | -$8.69M | – |
| Q4 FY2021 | Dec 31, 2021 | -$5.93M | – |
| Q3 FY2021 | Sep 30, 2021 | -$10.54M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.97M | – |
| Q1 FY2021 | Mar 31, 2021 | -$42.87M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.05M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.08M | – |
| Q2 FY2020 | Jun 30, 2020 | -$9.09M | – |
| Q1 FY2020 | Mar 31, 2020 | -$10.23M | – |
| Q4 FY2019 | Dec 31, 2019 | -$6.92M | – |
| Q3 FY2019 | Sep 30, 2019 | -$796.00K | – |
| Q2 FY2019 | Jun 30, 2019 | -$2.18M | – |
| Q1 FY2019 | Mar 31, 2019 | -$1.12M | – |
| Q4 FY2018 | Dec 31, 2018 | -$2.09M | – |
| Q3 FY2018 | Sep 30, 2018 | -$3.32M | – |
| Q2 FY2018 | Jun 30, 2018 | -$4.93M | – |
| Q1 FY2018 | Mar 31, 2018 | -$7.98M | – |
| Q4 FY2017 | Dec 31, 2017 | -$5.04M | – |
| Q3 FY2017 | Sep 30, 2017 | -$5.38M | – |
| Q2 FY2017 | Jun 30, 2017 | -$5.67M | – |
| Q1 FY2017 | Mar 31, 2017 | -$6.62M | – |
| Q4 FY2016 | Dec 31, 2016 | -$2.76M | – |
| Q3 FY2016 | Sep 30, 2016 | -$3.99M | – |
See a number that looks wrong?